Organovo Sells FXR IP for $10 Million in New Deal with Eli Lilly
Indianapolis pharmaceutical company Eli Lilly has acquired Organovo’s farnesoid X receptor (FXR) program. According to a recently filed Securities and Exchange Commission (SEC) document, Eli Lilly will make an upfront cash payment of $9 million, with an extra $1 million transferred after 15 months. Development, regulatory, and commercial landmarks could see Organovo receive an additional […]
Indianapolis pharmaceutical company Eli Lilly has acquired Organovo’s farnesoid X receptor (FXR) program. According to a recently filed Securities and Exchange Commission (SEC) document, Eli Lilly will make an upfront cash payment of $9 million, with an extra $1 million transferred after 15 months. Development, regulatory, and commercial landmarks could see Organovo receive an additional […]
